TY  - JOUR
T1  - Β-blocker use for patients with or at risk for coronary artery disease—reply
AU  - Bangalore S, Steg P, Bhatt DL
Y1  - 2013/02/06
N1  - 10.1001/jama.2012.128872
JO  - JAMA
SP  - 438
EP  - 438
VL  - 309
IS  - 5
N2  - 
The well-known fact that atenolol is ineffective has not translated into clinical practice—atenolol was the second top generic drug based on retail dollars in 2010.1 The data on β-blocker use in patients without heart failure are based on older agents and as a result, there is no guideline recommendation of a preferred β-blocker.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.128872
UR  - http://dx.doi.org/10.1001/jama.2012.128872
ER  -